PRESS RELEASE
June 18, 2012, 7:02 a.m. EDT
TORONTO, ONTARIO, Jun 18, 2012 (MARKETWIRE via COMTEX) -- Trimel Pharmaceuticals Corporation ("the "Company" or "Trimel") announced today that the Company recently hosted a two day meeting in Chicago with leading investigators in the study of new treatments for Female Sexual Dysfunction. The purpose of the meeting was to allow the Company to review the trial protocol for the Company's ambulatory ("AMB") Phase II clinical study investigating the use of Tefina(TM) for the treatment of Female Orgasmic Disorder ("FOD"), or more commonly referred to as anorgasmia. The Company also used the meeting to train clinical study coordinators to ensure consistent patient selection and diagnosis, as well as discuss strategies for optimal study conduct.
The Company intends to enroll 240 patients in its AMB Phase II study being initiated in both the United States and Canada, with additional sites in Australia expected to join the study in the third quarter of 2012. The primary efficacy endpoint of this ambulatory trial will be the increase in the occurrence of orgasm over the treatment period compared against baseline levels. Patients will receive Tefina(TM) or placebo at home instead of in a hospital setting.
The principal investigator for this study is Dr. Sheryl Kingsberg. Dr. Kingsberg is the Chief of Behavioral Medicine at University Hospitals Case Medical Center and Professor in Reproductive Biology and Psychiatry at Case Western Reserve University in Cleveland, Ohio. Dr. Kingsberg's primary research interests are in treatments for female sexual disorders and the psychological aspects of infertility and menopause. She is an active member in a number of national and international scientific organizations and is a past president of the International Society for the Study of Women's Sexual Health.
"I am pleased to have the opportunity to contribute my expertise to the design, planning and conduct of the Tefina(TM) ambulatory trial." said Dr. Kingsberg. "Women with Female Orgasmic Disorder have no approved pharmacological treatment options and Tefina(TM)'s innovative 'use as required' treatment approach, if approved, would help address this unmet need."
"It was quite encouraging to hear positive feedback from such an esteemed group of leading clinicians in the treatment of Female Orgasmic Disorder" said Bruce D. Brydon, Chairman and Chief Executive Officer. "In particular, we found tremendous enthusiasm for the first 'use-as-required' approach provided by Tefina(TM) to treat a condition which is estimated to affect one in five women worldwide."
About Tefina(TM)
Trimel's product candidate Tefina(TM) is a bioadhesive 'no touch' intranasal low-dose gel formulation of testosterone. Tefina(TM) is being developed to offer women with female orgasmic disorder, a "use as required" treatment option. Tefina(TM) is expected to present an attractive safety profile, with virtually no androgen-related side effects such as acne, facial and body hair growth or deepening of the voice. Moreover, there is no expected risk of skin-to-skin transfer of testosterone to third parties with the multi-dose dispenser.
About Female Orgasmic Disorder
Female Orgasmic Disorder (FOD) is defined as the persistent or recurrent delay in, or absence of, orgasm following normal sexual excitement phase that causes marked personal distress or interpersonal difficulties. The etiology of FOD is often characterized by whether the dysfunction has been lifelong (primary) or acquired (secondary). This condition affects 1 in 5 pre and post menopausal women worldwide. Currently there are no approved treatments for FOD and therefore represents an unmet need for women suffering distress from this condition.
About Trimel
Trimel Pharmaceuticals Corporation - Developing medications for Female Sexual Health and conditions related to Aging, and Well Being. Trimel is developing multiple product opportunities, including CompleoTRT(TM), a bio-adhesive intranasal Testosterone gel currently in Phase III clinical testing in the United States. CompleoTRT(TM) is under investigation for the treatment of male hypogonadism, a condition commonly referred to as "Low T". For more information, please visit www.trimelpharmaceuticals.com .
For further information regarding Trimel Pharmaceuticals Corporation, please contact either Bruce Brydon, Chairman of the Board and Chief Executive Officer at (416) 679-0711 or Kenneth Howling, Chief Financial Officer at (416) 679-0536 or via email at ir@trimelpharmaceuticals.com.
Notice regarding forward-looking statements:
This release contains forward looking information. This forward-looking information is not based on historical facts but rather on the expectations of the Company's management regarding the future growth of the Company and its respective results of operations, performance and business prospects and opportunities. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives or economic performance, or the assumptions underlying any of the foregoing. This release uses words such as "will", "expects", "anticipates", "intends", "estimates", or similar expressions to identify forward-looking information. Such forward-looking information reflects the current beliefs of the Company's management based on information currently available to them.
Forward-looking information included in this release is based in part, on assumptions that may change, thus causing actual future results or anticipated events to differ materially from those expressed or implied in any forward-looking information. Such assumptions include that: the Company will achieve, sustain or increase profitability, and will be able to fund its operations with existing capital, and/or it will be able to raise additional capital to fund operations; the Company will be able to attract and retain key personnel; the Company will be able to acquire any necessary technology or businesses and effectively integrate such acquisitions; the Company will be successful in developing and clinically testing products under development; the Company will be successful in obtaining all necessary approvals for commercialization of its products from the U.S. Food and Drug Administration, the Canadian Therapeutic Products Directorate or other regulatory authorities; the results of continuing and future safety and efficacy studies by industry and government agencies relating to the Company's products will be favourable; the Company's products will not be adversely impacted by competitive products and pricing; raw materials and finished products necessary for the Company's products will continue to be available; the Company will be able to maintain and enforce the protection afforded by any patents or other intellectual property rights; the Company's products will be successfully licensed to third parties to market and distribute such products on favourable terms; the Company's key strategic alliances, out licensing and partnering arrangements, now and in the future, will remain in place and in force; the general regulatory environment will not change in a manner adverse to the business of the Company; the tax treatment of the Company and its subsidiaries will remain constant and the Company will not become subject to any material legal proceedings. The Company cautions that the foregoing list of assumptions is not exhaustive.
Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information. Actual results, performance or achievement could differ materially from that expressed in, or implied by; any forward-looking information in this release, and, accordingly, investors should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made and the Company undertakes no obligation to update any forward-looking information to reflect the occurrence of unanticipated events, except as required by law including applicable securities laws. New factors emerge from time to time and the importance of current factors may change from time to time and it is not possible for management of the Company to predict all of such factors, changes in such factors and to assess in advance the impact of each such factor on the business of the Company or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information contained in this release.
Contacts:
Trimel Pharmaceuticals Corporation
Kenneth G. Howling
Chief Financial Officer
416 679 0536
ir@trimelpharmaceuticals.com
www.trimelpharmaceuticals.com
http://www.marketwatch.com/story/trimel-hosts-tefinatm-investigator-meeting-2012-06-18-7173137
